Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection (uUTI)

Exclusion Criteria

• •1. Presence of signs and symptoms suggestive of acute pyelonephritis: fever (temperature \> 38°Celsius), chills, costovertebral angle tenderness, flank pain, nausea and/or vomiting
• •2. Receipt of prior effective antibacterial drug therapy for uUTI for the presenting illness unless the recovered pathogen demonstrates resistance to initial antibiotic and clinical symptoms persist
• •3. Concurrent use of non-study antibacterial drug therapy that would have a potential effect on outcome evaluations in patients with uUTI
• •4. Patients with ileal loops or urinary stoma
• •5. Patients with an indwelling urinary catheter in the previous 30 days
• •6. Patients with paraplegia
• •7. Patients who are likely to receive ongoing antibacterial drug prophylaxis after treatment of uUTI (e.g., patients with vesico-ureteral reflux)
• •8. Any history of trauma to the pelvis or urinary tract
• •9. Patient's urine culture results, if available at study entry, identify more than 2 microorganisms regardless of colony count or patient has a potential fungal pathogen
• •10. Patient's urine culture results, if available at study entry, identifies the causative uropathogen for the presenting illness to be resistant to ciprofloxacin
• •11. Patient has severe chronic kidney disease, or is receiving hemodialysis or peritoneal dialysis or had a renal transplant
• •12. Patient is known to have severe neutropenia
• •13. Patient is known to be pregnant
• •14. Patients with uncontrolled diabetes mellitus
• •15. Patients with a known history of myasthenia gravis
• •16. Patients who require concomitant administration of tizanidine
• •17. Patients with a history of allergy to quinolones
• •18. Patient is considered unlikely to survive the study period or has a rapidly progressive or terminal illness including septic shock which is associated with a high risk of mortality